Detailed price information for Inhibrx Biosciences Inc (INBX-Q) from The Globe and Mail including charting and trades.

Irisleydi Trista Calzadilla, a Cuban woman suffering from a 20-centimeter malignant tumor in her spine, made an urgent plea ...

If approved, ozekibart would become the first and only approved systemic therapy for patients with unresectable or metastatic ...

Results showed ozekibart significantly reduced the risk of disease progression or death by 52% compared with placebo. The Food and Drug Administration (FDA) has accepted for review the Biologics ...

A novel tetravalent DR5 agonist could become the first standard of care for conventional chondrosarcoma.Updated data from the ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on ...

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

Elisabeth Finch resigned from 'Grey’s Anatomy' after an investigation revealed she had fabricated a cancer diagnosis Katie Mannion is a contributing writer at PEOPLE. She has been working at PEOPLE ...

If you find out that you have chondrosarcoma, it means you have a rare type of bone cancer. Usually, it grows and spreads slowly. Your doctor will likely suggest you get surgery to take out the tumor.

Recent trials reveal promising advancements in targeted therapies for chondrosarcomas and tenosynovial giant cell tumors. At the 4th Annual Miami Cancer Institute Precision Oncology Symposium on ...

Inhibrx Biosciences, Inc. ((INBX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...